Navigation Links
S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets
Date:1/6/2009

S*BIO Receives $25 Million Upfront Payment and Equity Investment and Eligible to Receive Additional $525 Million in Option & License Fees and Milestone Payments

SINGAPORE, Jan. 6 /PRNewswire/ -- S*BIO Pte Ltd today announced that the company has entered into a Development Collaboration, and Option & License Agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize S*BIO's novel JAK2 inhibitors, SB1518 and SB1578.

Under the terms of the agreement, S*BIO is eligible to receive up to $550 million in combined equity purchase, option & license fees, and development and sales milestone payments. This includes an upfront payment and upfront equity purchase totaling $25 million. S*Bio is also eligible to receive up to double digit royalties on any sales.

S*BIO will perform all the clinical development activities for SB1518 and preclinical to clinical development activities for SB1578 during the option period. Onyx can elect to exercise its exclusive options for SB1518 and SB1578 at certain predetermined stages of development for each product separately and independently. Each option converts into an exclusive license for development and commercialization rights for SB1518 and SB1578 in all indications in the United States, Canada and Europe where Onyx will assume all of the associated development costs. S*BIO has a co-funding option with respect to these development costs in return for enhanced royalties on any future product sales. S*BIO retains rights to develop and commercialize SB1518 and SB1578 in the rest of the world.

The development of SB1518 will initially focus on the treatment of myelofibrosis and other myeloproliferative diseases. JAK2 inhibitors are implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases.

"We are pleased to work with Onyx Pharmaceuticals and increase available reso
'/>"/>

SOURCE S*BIO
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
2. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. MHA Announces Pegeen Butterfield, RN as Senior Vice President of Trade Relations
5. IMRIS announces first IMRISneuro project in Australia
6. Akrimax Pharmaceuticals Announces Manufacturing Partnership
7. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
8. American Asthma Foundation Announces Breakthrough Discovery
9. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
10. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
11. DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... Those looking to catch a new and refreshing show on Broadway, look no further ... achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel ...
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Transfinder, a software ... , Total sales were up 16 percent year-over-year for the first six months ended ... Civitella said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Mullin/Ashley Associates , ... the 2015 Aster Awards national competition for a marketing communications campaign created for ... surrounding communities in Coastal Maryland and Southern Delaware. , A Bronze Award was ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... new test that screens babies for the presence of a ... on Tuesday. Group B streptococcus// is a common infection that ... pneumonia, meningitis, neurological damage or even death. ,Although ... current screening methods can leave some babies at risk for ...
... the mind are really mysterious, however these have inspired ... of the brain affected by the// personality disorder schizophrenia. ... into a tool that can help diagnose the condition. ... of people with schizophrenia is yet to be pinned ...
... medication have long been the cornerstones of managing type ... benefits// these patients. ,Now, a new systematic ... levels, increases the body’s sensitivity to insulin, and decreases ... fat. ,“Type 2 diabetes is an increasing ...
... by Satish K. Pillai, PhD, a staff research associate at ... San Francisco it was found that HIV in the brain ... ,The patients suffered severe to moderate cognitive decline. ... a particular mutation in the HIV envelope gene. The study ...
... pilgrim died of respiratory problems while on a tour ... woman too succumbed// to high-altitude illness while pursuing the ... pilgrim sites in Asia is fast turning into a ... Devi Shriram Bhoyar, a 38-year-old god woman from Maharashtra, ...
... Sandip Datta and Joshua Fierer of the University of ... gamma radiation// killed bacteria are very effective in inducing ... ,The U.S. National Institute of Allergy and Infectious ... said that these bacterial cultures could be used as ...
Cached Medicine News:Health News:FDA Approves New Test For Screening Infection In Babies 2Health News:FDA Approves New Test For Screening Infection In Babies 3Health News:Diagnosing Schizophrenia 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3Health News:Mutation in the Envelope Gene May Be the Reason for the Development of HIV Linked Cognitive Decline 2Health News:High-altitude Illness Affects Pilgrims of Mansarovar 2
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... a press release on July 28, 2015, "Surviving ... Safety Launches Fundraising for Patient Safety." ... last sentence should read: "PPAHS is ... of Patients on Opioids. For more information on the ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... Oct. 26 Palomar Pomerado Health (PPH), a Magnet® ... has been selected by San Diego-based CareFusion, a global ... latest Pyxis technologies that focus on improving the safety ... partner in innovation with CareFusion, PPH physicians, nurses, pharmacists, ...
... Oct. 26 Nautilus Neurosciences, Inc., a neurology-focused specialty ... pivotal safety and efficacy studies of CAMBIA™ (diclofenac potassium ... World Congress on Controversies in Neurology Conference (CONy) in ... presented in a poster (#23) entitled, "Rapid and Sustained ...
Cached Medicine Technology:CareFusion Selects Palomar Pomerado Health as Development Partner for Patient Safety Technologies 2CareFusion Selects Palomar Pomerado Health as Development Partner for Patient Safety Technologies 3New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 2New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 3New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 4